Eskalith and Levaquin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eskalith (lithium carbonate) and Levaquin (levofloxacin). Common drug interactions include schizoaffective disorder among females and acute respiratory distress syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Eskalith and Levaquin. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Eskalith?

Eskalith has active ingredients of lithium carbonate. eHealthMe is studying from 1,448 Eskalith users. Check the latest studies of Eskalith.

What is Levaquin?

Levaquin has active ingredients of levofloxacin. It is often used in sinusitis. eHealthMe is studying from 56,638 Levaquin users. Check the latest studies of Levaquin.



On Jul, 12, 2026

14 people who take Eskalith and Levaquin together, and have interactions are studied.

Eskalith and Levaquin drug interactions.

What are the common drug interactions of Eskalith and Levaquin, by gender? *:

female:

  1. Schizoaffective disorder (a mental disorder characterized by disordered thought)
  2. Skin warm
  3. Spinal pain (pain in spine)
  4. Suicidal ideation
  5. Tenderness (pain or discomfort when an affected area is touched)
  6. Tinea infection (fungal skin infection)
  7. Tongue coated
  8. Type 1 diabetes mellitus
  9. Type 2 diabetes mellitus
  10. Ulcer

male:

  1. Acute respiratory distress syndrome
  2. Adverse drug reaction
  3. Abdominal discomfort
  4. Abdominal pain
  5. Dehydration (dryness resulting from the removal of water)
  6. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  7. Epistaxis (bleed from the nose)
  8. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  9. Haematuria (presence of blood in urine)
  10. Haemoglobin decreased

What are the common drug interactions of Eskalith and Levaquin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Epistaxis (bleed from the nose)
  2. Fatigue (feeling of tiredness)
  3. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  4. Haematuria (presence of blood in urine)
  5. Haemoglobin decreased
  6. Hypertension (high blood pressure)
  7. Hypotension (abnormally low blood pressure)
  8. Mania (a state of abnormally elevated or irritable mood)
  9. Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
  10. Obesity (having too much body fat)

40-49:

  1. Acute respiratory distress syndrome
  2. Adverse drug reaction
  3. Cerebral haemorrhage (bleeding within the brain)
  4. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  5. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  6. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  7. Loss of consciousness
  8. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  9. Renal failure acute (rapid kidney dysfunction)
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

50-59:

n/a

60+:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Erythema (redness of the skin)
  3. Balance disorder
  4. Blood creatinine increased
  5. Blood glucose decreased
  6. Blood pressure increased
  7. Catheter site erythema (redness of skin at catheter site)
  8. Catheter site infection (infection at the site of insertion)
  9. Catheter site pain
  10. Cellulitis (infection under the skin)

What are the existing conditions these people have? *

  1. Bipolar Disorder (mood disorder): 5 people, 35.71%
  2. Sleep Disorder: 2 people, 14.29%
  3. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 7.14%
  4. Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 7.14%
  5. Pancreatic Carcinoma (pancreatic cancer): 1 person, 7.14%
  6. Insomnia (sleeplessness): 1 person, 7.14%
  7. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 7.14%
  8. Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 1 person, 7.14%
  9. Asthma: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Eskalith and Levaquin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Eskalith and Levaquin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Eskalith:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Levaquin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Eskalith and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Levaquin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on lithium carbonate and levofloxacin (the active ingredients of Eskalith and Levaquin, respectively), and Eskalith and Levaquin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: